Passage Bio Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$36.1MTTM through 30 Jun 2026
Free Cash Flow -$33.5MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-321.0%ROE
-103.0%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio1.73x
Net Debt-$33.3Mnet cash position
Cash & Equivalents$24.2M
Quality Metrics
Altman Z-Score-44.49
Piotroski F-Score2 / 9
Earnings-Beat Rate66.7%
Multi-Year Trend
Diluted EPS-$11.32TTMFY2025: $-14.35
Dividend
No dividend
Capital Allocation
R&D Spend$17.2M
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.